BHVN
Biohaven Ltd.
NYSEUSDEQUITY
Healthcare
DELAYED
Last price
14.12
▲ 0.62 (4.59%)
MARKET · —
Price
Open
13.50
Prev close
13.50
Day high
14.33
Day low
13.53
Volume
2.09M
Market cap
$2.09B
P/E (TTM)
—
52W range
7.48 – 18.57
Trailing performance
Returnvs SPY
1W
-5.40%
-4.0%
1M
-5.46%
-9.2%
3M
+46.10%
+43.0%
6M
+23.33%
+12.3%
YTD
+22.67%
+10.4%
1Y
-5.78%
-25.8%
3Y
-30.33%
-104.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$2.09B
Enterprise value$2.12B
Revenue (TTM)—
Gross profit—
EBITDA$-520.11M
Net income$-586.84M
EPS (TTM)$-4.55
Free cash flow$-256.22M
Total cash$267.87M
Total debt$297.04M
Book value / share$0.08
Shares outstanding151.04M
Float116.57M
Short % of float15.41%
Dividend yield—
Beta (5Y)3.16
Valuation & profitability ratios
Trailing P/E—
Forward P/E-6.97
PEG ratio—
Price / sales—
Price / book170.99
EV / revenue—
EV / EBITDA-4.08
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-799.46%
Return on assets-71.98%
Debt / equity2,430.33
Current ratio4.73
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$738.82M | -$846.42M | -$408.17M | -$570.28M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$738.82M | -$846.42M | -$408.17M | -$570.28M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.61 | -0.78 | -27.6% |
| Dec 2025 | -0.96 | -0.90 | +5.8% |
| Sep 2025 | -1.93 | -1.64 | +14.9% |
| Jun 2025 | -1.57 | -1.63 | -4.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.61 | 8 | $0 | 0.0% |
| Next quarter | -0.57 | 3 | $0 | 0.0% |
| Current year | -2.64 | 3 | $0 | 0.0% |
| Next year | -1.99 | 6 | $21.42M | 0.0% |
Analyst targets & ownership
Mean target$23.07
High target$50.00
Low target$10.00
Implied upside63.36%
Analyst count15
ConsensusBUY
Strong buy / Buy4 / 9
Hold3
Sell / Strong sell0 / 1
Held by insiders11.21%
Held by institutions96.65%
Institutions holding377
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
16.92M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Mar 17, 26 | MEHTA KISHAN Director |
STOCK | 17.34K | $0 | Direct |
| Jan 5, 26 | GENTILE KIMBERLY A Officer |
— | 3.75K | — | Direct |
| Jan 5, 26 | CORIC VLADIMIR Chief Executive Officer |
— | 14.25K | — | Direct |
| Jan 5, 26 | CAR BRUCE Officer |
— | 4.75K | — | Direct |
| Jan 5, 26 | CLARK GEORGE C. Officer |
— | 2.50K | — | Direct |
| Jan 5, 26 | BUTEN MATTHEW Chief Financial Officer |
— | 4.25K | — | Direct |
| Nov 17, 25 | CLARK GEORGE C. Officer |
BUY | 17.00K | $144.77K | Indirect |
| Nov 13, 25 | CHILDS JOHN W Director |
BUY | 3.33M | $25.00M | Indirect |
| Nov 13, 25 | BAILEY GREGORY HUGH Director |
BUY | 400.00K | $3.00M | Direct |
| Nov 13, 25 | CORIC VLADIMIR Chief Executive Officer |
BUY | 666.67K | $5.00M | Indirect |
| Mar 4, 25 | CHILDS JOHN W Director |
BUY | 32.70K | $996.24K | Indirect |
| Mar 4, 25 | CHILDS JOHN W Director |
BUY | 29.30K | $891.77K | Indirect |
| Jan 3, 25 | GENTILE KIMBERLY A Officer |
— | 3.75K | — | Direct |
| Jan 3, 25 | CORIC VLADIMIR Chief Executive Officer |
— | 14.25K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BAILEY GREGORY HUGH |
Director | 2.02M | Purchase |
BUTEN MATTHEW |
Chief Financial Officer | 195.65K | Conversion of Exercise of derivative security |
CAR BRUCE |
Officer | 37.72K | Conversion of Exercise of derivative security |
CHILDS JOHN W |
Director | — | Purchase |
CLARK GEORGE C. |
Officer | 86.98K | Conversion of Exercise of derivative security |
CORIC VLADIMIR |
Chief Executive Officer | 3.85M | Conversion of Exercise of derivative security |
GENTILE KIMBERLY A |
Officer | 99.56K | Conversion of Exercise of derivative security |
MEHTA KISHAN |
Director | 22.66K | Stock Gift |
Moving averages & technicals
SMA 10
14.24
-0.86% from price
SMA 20
14.06
-1.53% from price
SMA 50
14.45
-4.16% from price
SMA 100
12.18
+15.92% from price
SMA 200
11.38
+21.71% from price
EMA 12
14.10
+0.14% from price
EMA 26
14.18
-0.45% from price
EMA 50
13.81
+2.26% from price
RSI (14)
47.0
Neutral
MACD (12,26,9)
-0.08
Hist -0.08
ATR (14)
0.72
5.21% of price
Realised vol 30D
54.8%
Annualised
Bollinger upper
15.02
20, 2σ
Bollinger lower
13.11
20, 2σ
50 / 200 cross
Golden
14.45 vs 11.38
Trend bias
Above 200
+21.71%
Risk profile
Beta vs SPY
1.11
More volatile than market
Correlation to SPY
0.16
Largely independent
Realised vol 30D
54.8%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-57.0%
Peak to trough
Max drawdown 5Y
-87.0%
Peak to trough
ATR 14
0.72
5.21% of price
Beta (reported)
3.16
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.09
Call-heavy session
Put / call open interest
0.04
Positioning, not flow
Max pain
13.00
-6.1% from spot
ATM implied vol
84.6%
Nearest strike to spot
Skew (10% OTM)
+3.8%
Puts bid over calls
Call volume
342
Contracts, this expiry
Put volume
31
Contracts, this expiry
Heaviest call OI
15.00
1.36K contracts
Heaviest put OI
13.00
69 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Regeneron (REGN) Stock Looks Undervalued On Expanded Cancer Collaboration News
Simply Wall St. · 2d ago
Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline?
Insider Monkey · 8d ago
Biohaven Supported by Multiple Pipeline Catalysts, Cash Runway Into 2027, RBC Says
MT Newswires · 11d ago
RBC Adjusts Price Target on Biohaven to $23 From $22, Maintains Outperform Speculative Risk Rating
MT Newswires · 11d ago
Biohaven Q2 Adjusted Loss Narrows
MT Newswires · 12d ago
Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results
PR Newswire · 12d ago
Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors
PR Newswire · 16d ago
Biohaven Awarded $1 Million Over Alleged Trade Secret Violations by Avilar Therapeutics, RA Capital Management
MT Newswires · 26d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.